From SARS-CoV to Coronavirus Disease 2019 (COVID-19) - A Brief Review
SARS-CoV to Coronavirus Disease 2019
Abstract
Emerging and reemerging pathogens are global challenges for public health. For the third time in as many decades, a zoonotic coronavirus has crossed species to infect human populations. Given the Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) outbreak in 2002 and the Middle East Respiratory Syndrome Coronavirus (MERS-CoV) outbreak in 2012, 2019-nCoV is the third coronavirus to emerge in the human population in the past 18 years-an outbreak that has raised great hue and cry globally as it has sickened thousands of people across the world. This novel coronavirus was named as COVID-19 which stands for Corona Virus Disease 2019. The 2019-nCoV originated from Wuhan, Hubei Province, China beginning in December 2019. The World Health Organization declared it as a Public Health Emergency of International Concern. At that point, there were 9826 confirmed cases globally, with 213 deaths. Of these, 9720 cases were in China; outside of China, health authorities reported 106 confirmed cases in 19 countries. As of February 2, the WHO updated the count, reporting 14 557 confirmed cases from 24 countries-14 411 of them in China. In this review we focus our attention on Covid-19 and how different this epidemic is from the previous two outbreak caused by coronavirus.
References
Poudel Adhikari S, Meng S, Wu Y, Mao Y, Ye R, Wang Q, et al. A Literature Review of 2019 Novel Coronavirus
during the Early Outbreak Period: Epidemiology, Causes, Clinical Manifestation and Diagnosis, Prevention and
Control. Medicine & Pharmacology; 2020 Feb [cited 2020 Feb 11].
Su S, Wong G, Shi W et al. Epidemiology, genetic recombination, and pathogenesis of coronaviruses.
Trends Microbiol 2016; 24: 490-502.
Tyrrel DAJ, Almedia JD, Berry DM, Cunningham CH, Hamre D, Hofstad MS et al. Coronavirus. Nature 1968;
: 650.
McIntosh K. Coronaviruses: a comparative review. Curr Top Microbiol Immunol 1974; 63: 85-129.
Cui J, Li F, Shi ZL et al. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol 2019; 17: 181-192.
Woo PC, Lau SK, Chu CM. Characterization and complete genome sequence of a novel coronavirus, coronavirus HKU1, from patients with pneumonia. J Virol 2005; 79: 884-895.7. Fouchier RA, Hartwig NG, Bestebroer TM, Niemeyer B, de Jong JC, Simon JH et al. A previously undescribed coronavirus associated with respiratory disease in humans. Proc Natl Acad Sci. 2004; 101: 6212-6216.
Van der Hoek L, Sure K, Ihorst G, Stang A, Pyrc K, Jebbink MF et al. Croup is associated with the novel
coronavirus NL63. PLoS Med 2005; 2:e 240.
Wevers BA, van der Hoek L. Recently discovered human coronaviruses. Clin Lab Med 2009; 29: 715-724.
Report of clustering pneumonia of unknown aetiology in Wuhan City. Wuhan Municipal Health Commission,
(http://wjw .wuhan .gov .cn/ front/ web/ show Detail/ 2019123108989).
Lu R, Zhao X, Li J, Niu P, Yang B, Wu H et al. Genomic characterisation and epidemiology of 2019 novel
coronavirus: implications for virus origins and receptor binding. The Lancet 2020; S0140673620302518.
Hu D, Zhu C, Ai L et al. Genomic characterization and infectivity of a novel SARS-like coronavirus in Chinese
bats. Emerg Microbes Infect 2018; 7: 154.
Alagaili AN, Briese T, Mishra N et al. Middle East respiratory syndrome coronavirus infection in
dromedary camels in Saudi Arabia. mBio 2014; 5: e00884-14.
Li F, Li W, Farzan M, Harrison SC. Structure of SARS coronavirus spike receptor-binding domain complexed
with receptor. Science 2005; 309: 1864-1868.
Wang Q, Wong G, Lu G, Yan J, Gao GF. MERS-CoV spike protein: targets for vaccines and therapeutics. Antiviral
Res 2016; 133: 165-77.
Chan JFW, Yuan S, Kok KH et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus
indicating person-to-person transmission: a study of a family cluster. Lancet 2020; published online Jan 24.
World Health Organization. Coronavirus disease (COVID-2019) situation reports (https://www.who.
int/emergencies/ diseases/novel-coronavirus-2019/situation -reports/).
Huang C, Wang Y, Li X et al. Clinical features of patients infected with 2019 novel corona virus in Wuhan, China. [published January 24, 2020]. Lancet 2020.
Dawei Wang, Bo Hu, Chang Hu, Fangfang Zhu, Xing Liu, Jing Zhang et al. Clinical Characteristics of 138
Hospitalized Patients with 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China. JAMA 2020.
DOI: 10.1001/jama.2020.1585.
Guan W, Ni Z, Hu Y, Liang W, Ou C, He J et al. Clinical Characteristics of Coronavirus Disease 2019 in China.
N Engl J Med 2020; DOI: NEJMoa2002032.
World Health Organization. Novel coronavirus(2019-nCoV) situation report-15. Published February 4, 2020.
LiQ, GuanX, WuP et al. early transmission dynamics in Wuhan, China, of novel coronavirus-infected
pneumonia. [published on January29,2020]. N Engl J Med. 2020.
National Health Commission, China. Pneumonia diagnosis and treatment of 2019-nCoV infection from
Chinese NHC and CDC 2020.
Li g, De Clercq E, Therapeutic Options for the 2019 novel coronavirus(2019-nCoV). Nature Reviews Drug
Discovery 2020.
Ko WC, Rolain JM, Lee NY, Chen PL, Huan CT, Lee PI et al. Arguments in favoe of remdesvir for treating SARSCoV2 infections. International Journal of Antimicrobial Agents 2020: 105933.
Coronavirus Disease 2019 (COVID-19)â€. Centers for Disease Control and Prevention. 11 February 2020.
Retrieved 11 March 2020.
Kim UJ, Won EJ, Kee SJ, Jung SI, Jang HC. Combination therapy with lopinavir/ritonavir, ribavirin and interferonalpha for Middle East respiratory syndrome. Antivir Ther 2016; 21: 455-459.
Global surveillance for COVID-19 disease caused by human infection with the 2019 novel coronavirus
-ncov)).
US Centres for Disease Control and Prevention. Novel coronavirus, Wuhan, China: symptoms. 2019.
Chowell G, Castillo-Chavez C, Fenimore PW Model et al parameters and outbreak control for SARS. Emerg
Infect Dis 2004; 10(7): 1258-1263.
